Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema

NCT07106268 | Active Not Recruiting

• 1 other identifier: MR-12-24-035937
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

the goal of this observational study is to the find the molecular mechanisms underlying the prognosis process of Retinal vein occlusion in patients with retinal vein occlusion . The main question it aims to answer is: What are the changes in protein in the aqueous humor during treatment in patients who are sensitive to anti-VEGF drug therapy?

Conditions

Retinal Vein Occlusion

Outcome Measures

Primary Outcomes (1)

• Central retinal thickness

  The Heidelberg Optical Coherence Tomography scanner was used to detect the central retinal thickness in patients

  March 2023 - June 2024

Secondary Outcomes (1)

• Best corrected visual acuity

  March 2023 - June 2024

Study Arms (3)

Patients with central retinal vein occlusion

Received three injections of the anti-VEGF drug Conbercept

Patients with branch retinal vein occlusion

Received three injections of the anti-VEGF drug Conbercept

Cataract patients without other eye diseases and other chronic diseases

Undergo cataract surgery

Eligibility Criteria

• Age: 20 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with retinal vein occlusion with macular edema

You may qualify if:

• Cystic or diffuse edema in the macular area, retinal vein tortuous dilation with hemorrhage
• Optical coherence tomography (OCT) examination showed that the macular area was raised, edema and thickened
• Monocular disease, baseline central retinal thickness (CRT) ≥ 250mm
• Intravitreal injection, laser photocoagulation and blood circulation and blood stasis removal drugs were not treated before surgery
• The patient had normal blood pressure, negative urine protein, normal liver and kidney function, and normal electrocardiogram

You may not qualify if:

• Patients with fluorescein fundus angiography (FFA) showing a large area (10 optic disc areas) without perfusion requiring retinal photocoagulation
• Patients with chronic dacryocystitis, glaucoma, cataract, severe proliferative vitreoretinopathy or vitreous hemorrhage, epi macular membrane or macular ischemia, diabetic retinopathy, age-related macular degeneration, ocular trauma and other diseases
• Intravitreal therapy or laser photocoagulation with corticosteroids or anti-VEGF drugs within three months before the study

Sponsors & Collaborators

• Tianjin Medical University Eye Hospital: lead

Study Sites (1)

Tianjin medical university eye hospital

Tianjin, Province, 300384, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Aqueous humor

MeSH Terms

Conditions

Retinal Vein Occlusion

Condition Hierarchy (Ancestors)

Retinal Diseases; Eye Diseases; Venous Thrombosis; Thrombosis; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 3 Months
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal investigator

Study Record Dates

• First Submitted: July 30, 2025
• First Posted: August 6, 2025
• Study Start: March 1, 2023
• Primary Completion: September 30, 2025
• Study Completion: September 30, 2025
• Last Updated: August 7, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)